US2023109336A1PendingUtilityA1

Selective extension in single cell whole transcriptome analysis

Assignee: BECTON DICKINSON COPriority: Dec 13, 2018Filed: Sep 30, 2022Published: Apr 6, 2023
Est. expiryDec 13, 2038(~12.4 yrs left)· nominal 20-yr term from priority
Inventors:Eleen Shum
C12N 15/1096C12Q 1/6837C12N 15/1093C12Q 1/6855C12Q 1/6806
72
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed herein include methods and compositions for selectively amplifying and/or extending nucleic acid target molecules in a sample. The methods and compositions can, for example, reduce the amplification and/or extension of undesirable nucleic acid species in the sample, and/or allow selective removal of undesirable nucleic acid species in the sample.

Claims

exact text as granted — not AI-modified
1 - 16 . (canceled) 
     
     
         17 . A kit for selective amplification of nucleic acid molecules in a sample, comprising:
 a plurality of oligonucleotide probes, wherein each of the plurality of oligonucleotide probes comprises a molecular label sequence and a target binding region comprising a poly-dT sequence; and   a plurality of blocking oligonucleotides that specifically binds to a plurality of undesirable mRNA species in the sample, wherein the plurality of blocking oligonucleotides binds to the non-poly(A) region of the plurality of undesirable mRNA species, and wherein each blocking oligonucleotide probe is unable to function as a primer for a reverse transcriptase or a polymerase.   
     
     
         18 . The kit of  claim 17 , wherein at least one of the plurality of oligonucleotide probes comprises one of the plurality of blocking oligonucleotides. 
     
     
         19 . The kit of  claim 17 , wherein one of the plurality of blocking oligonucleotides comprises (i) a sequence that specifically binds to at least one of the plurality of undesirable nucleic acid species, and (ii) a poly-dT sequence, and/or (iii) a sequence that does not hybridize to the at least one of the plurality of undesirable nucleic acid species. 
     
     
         20 . The kit of  claim 17 , wherein the blocking oligonucleotide comprises a 3′ non-annealing region configured to not anneal to the one or more undesirable nucleic acid species. 
     
     
         21 . The kit of  claim 20 , wherein the non-complementarity between the 3′ non-annealing region and the region of the undesirable nucleic acid species 5′ adjacent to the sequence specifically bound by the blocking oligonucleotide is at least 50%, is at least 60%, is at least 70%, is at least 80%, is at least 90%, is at least 95%, or is about 100%. 
     
     
         22 . The kit of  claim 17 , wherein the blocking oligonucleotide is a locked nucleic acid (LNA), a peptide nucleic acid (PNA), a DNA, an LNA/PNA chimera, an LNA/DNA chimera, or a PNA/DNA chimera. 
     
     
         23 . The kit of  claim 17 , wherein the plurality of oligonucleotide probes is immobilized on a particle. 
     
     
         24 . The kit of  claim 17 , wherein each blocking oligonucleotide probe has a T m  of at least 60° C. 
     
     
         25 . The kit of  claim 17 , wherein the blocking oligonucleotide does not comprise non-natural nucleotides. 
     
     
         26 . The kit of  claim 19 , wherein the poly-dT sequence of the oligonucleotide probe is longer than the poly-dT sequence of the blocking oligonucleotide. 
     
     
         27 . The kit of  claim 19 , wherein the poly-dT sequence of the oligonucleotide probe and the poly-dT sequence of the blocking oligonucleotide have an identical length. 
     
     
         28 . The kit of  claim 17 , wherein none of the plurality of oligonucleotide probes comprises the blocking oligonucleotide. 
     
     
         29 . The kit of  claim 20 , wherein the 3′ non-annealing region is 1 nt to 100 nt long, is 1 nt to 50 nt long, is 1 nt to 21 nt long, is 1 nt to 10 nt long, or is about 5 nt long. 
     
     
         30 . The kit of  claim 17 , wherein the plurality of blocking oligonucleotides specifically binds to two or more undesirable nucleic acid species. 
     
     
         31 . The kit of  claim 17 , wherein the blocking oligonucleotide is 8 nt to 100 nt long. 
     
     
         32 . The kit of  claim 17 , wherein the plurality of undesirable mRNA species comprises ribosome mRNA, mitochondrial mRNA, or a combination thereof. 
     
     
         33 . The kit of  claim 17 , wherein the blocking oligonucleotides specifically bind to within 100 nt of the 3′ end of the undesirable nucleic acid species. 
     
     
         34 . The kit of  claim 17 , wherein the plurality of oligonucleotide probes are immobilized on a substrate, and wherein the substrate is a particle. 
     
     
         35 . The kit of  claim 17 , further comprising an enzyme selected from the group consisting of a reverse transcriptase, a polymerase, a ligase, a nuclease, and a combination thereof. 
     
     
         36 . The kit of  claim 17 , wherein the plurality of blocking oligonucleotides specifically binds to at least 50 undesirable nucleic acid species.

Join the waitlist — get patent alerts

Track US2023109336A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.